This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
by Zacks Equity Research
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
KRYSNegative Net Change CSTLPositive Net Change INDVPositive Net Change
biotechs
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
by Zacks Equity Research
Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
VRTXPositive Net Change AGENPositive Net Change AMRNPositive Net Change CRSPPositive Net Change
biotechs earnings
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
by Zacks Equity Research
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
JAZZPositive Net Change AXSMPositive Net Change CSTLPositive Net Change INDVPositive Net Change
biotechs
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
by Ekta Bagri
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
VRTXPositive Net Change CRSPPositive Net Change CSTLPositive Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical pharmaceuticals
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
by Zacks Equity Research
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
GSKPositive Net Change MRKPositive Net Change SMMTPositive Net Change CSTLPositive Net Change
biotechs
ImmunityBio to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.
UTHRPositive Net Change ANIPPositive Net Change ACADPositive Net Change IBRXPositive Net Change
biotechs
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.
NVONegative Net Change AGENPositive Net Change INOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
by Sundeep Ganoria
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
NVAXPositive Net Change SRPTNegative Net Change CYTKPositive Net Change ANIPPositive Net Change RVMDPositive Net Change
biotechs earnings medical pharmaceuticals vaccines